Group of companies «Velpharm Group» — is a pharmaceutical holding company whose development strategy is to create a modern business ecosystem for the production of medicinal products in a full cycle, from pharmaceutical substances to finished dosage forms.

More than 2 000 highly qualified employees work at the enterprises of the Velpharm Group of Companies.

Velpharm Group today is 4 modern high-tech production sites for the production of medicines:

— 2 sites for the production of Finished dosage forms (t. Kurgan / Moscow, Zelenograd JSC)

— 2 sites for the production of Active pharmaceutical substances (t. Kurgan / t. Dolgoprudny)

Velpharm Group has its own R&D center which allows it to implement projects of any complexity: form the creation of a molecule to the industrial production of a drug, and to develop original technologies for the synthesis of pharmaceutical substances of various origins.

Currently, Velpharm-Group produces more than 300 types of drugs of various therapeutic groups and forms of release.

More than 150 drugs are at various stages of development and registration, including biotechnological drugs for the treatment of various autoimmune, neurological and oncological diseases, antitumor and hormonal drug, inhalation drugs, etc.

A third of the drugs have never been produced in Russia before.

Thus, at present using the original technology of Velpharm-Group, we have launched our own full-cycle production of sodium heparin and, based on it, low-molecular heparins, as well as the most popular anesthetic – Propofol, iron-containing antianemic agents and a whole range of others.

Currently, the original technology of Velpharm-Group is used to organize the full cycle production of highly demanded drugs — antithrombotic agents Sodium Heparin and low molecular weight heparins based on it, the most demanded anesthetic — Propofol, iron-containing antianemic agents and a number of others.

Currently more than 25 pharmaceutical substances are produced at Velpharm Group facilities, more than 50 are in development and their production is planned for 2025-2026.

In the first quarter of 2025, the production of sterile medicinal products and soft gelatin capsules was organized at the Velpharm-M plant in Moscow.

The construction of the 2nd production building has begun. This is a modern production facility using isolator technologies for the production of medicines with high pharmacological activity.

It is planned to release drugs for the treatment of patients suffering from cancer, autoimmune diseases, respiratory diseases and diseases requiring hormone therapy.